Domo signs strategic collaboration agreement with AWS for AI solutions
OAK RIDGE, TN - Daxor Corporation (NASDAQ:DXR), a leader in blood volume measurement technology trading at $7.56 per share, has announced substantial progress in various business areas, according to a shareholder letter from CEO Michael Feldschuh. According to InvestingPro data, the company’s stock shows unique characteristics with a beta of -0.53, indicating it often moves contrary to broader market trends. The company reported revenue growth, increased customer acquisitions, and strategic developments including an agreement to acquire a key supplier.
In 2024, Daxor achieved a 116.5% year-on-year revenue increase and continued this momentum into the first two months of 2025 with over 100% revenue growth compared to the same period in 2024. The number of kits sold for their Diagnostic System rose by 60.1% in 2024 versus 2023.
Financially, Daxor’s net assets as of December 31, 2024, were $36.8 million, or $7.25 per share, up from $34 million, or $7.08 per share on December 31, 2023. The valuation of the operating division increased by $3.5 million to $35.5 million. InvestingPro analysis reveals the company operates with a moderate debt level, with a debt-to-equity ratio of 0.05, though its current ratio of 0.28 indicates potential liquidity challenges. Net dividend income for the year ended December 31, 2024, was reported at $104,115, with net realized gains on investment activity of $1,359,163.
The company’s operating division met its goal of achieving cash-flow break-even during Q1 of 2025, excluding certain costs. Further, Daxor has successfully completed additional testing data requested by the FDA for its next-generation blood volume analyzer and plans to file a resubmission imminently.
Strategically, Daxor entered into an agreement to acquire intellectual property from its supplier, which is expected to be immediately cash flow positive and accretive to earnings. This move is intended to internalize production and increase margins on blood volume analysis test kits. The acquisition also includes Glofil, a drug for measuring glomerular filtration rate, which Daxor plans to cross-sell to its growing customer base.
The company has also been active in research, with studies utilizing blood volume analysis (BVA) published in more than a dozen peer-reviewed conferences or publications, highlighting the utility of BVA in various medical conditions.
Daxor anticipates significant interest in its new systems upon FDA approval, with potential broad changes in medicine and increased adoption in both hospital and outpatient settings. The company is also eligible to refile under its previous designation as an operating company, given the increased value of its operating division. Analyst expectations remain bullish, with price targets ranging from $22 to $24.75, significantly above current trading levels. For deeper insights into Daxor’s valuation and growth prospects, including additional ProTips and detailed financial metrics, investors can access comprehensive analysis through InvestingPro.
This update is based on a press release statement from Daxor Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.